Last reviewed · How we verify
Gefitinib and capecitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Gefitinib and capecitabine (Gefitinib and capecitabine) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gefitinib and capecitabine TARGET | Gefitinib and capecitabine | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gefitinib and capecitabine CI watch — RSS
- Gefitinib and capecitabine CI watch — Atom
- Gefitinib and capecitabine CI watch — JSON
- Gefitinib and capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). Gefitinib and capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/gefitinib-and-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab